Drilldown: Medicines

None (2) · Ciclopirox (1)

Ajovy (1) · Emgality (1) · Penlac (nail lacquer), Loprox (cream/lotion/shampoo) (1)

Anti-CGRP ligand monoclonal antibody (2) · [[:Category:Antifungals|Antifungal]] (1) · [[:Category:Hydroxypyridones|Hydroxypyridone]] (1) · [[:Category:Topical_antifungals|Topical antifungal]] (1)

Humanized IgG2 monoclonal antibody binding both isoforms of CGRP peptide (1) · Humanized IgG4 monoclonal antibody binding CGRP peptide; prevents CGRP from activating its receptor (1) · '"`UNIQ--vote-00001233-QINU`"' Onychomycosis cure rates with nail lacquer are modest (mycologic cure ~30-50%, complete cure ~5-12% at 48 weeks); oral terbinafine remains substantially more effective when systemic therapy is acceptable'"`UNIQ--ref-00001234-QINU`"'. (1)

Preventive treatment of migraine in adults (episodic and chronic) (1) · Preventive treatment of migraine in adults; episodic cluster headache (1) · '"`UNIQ--vote-00001235-QINU`"', '"`UNIQ--vote-00001236-QINU`"', '"`UNIQ--vote-00001237-QINU`"', '"`UNIQ--vote-00001238-QINU`"' (1)

225 mg SC monthly, or 675 mg SC every 3 months (quarterly) (1) · Migraine: 240 mg SC loading dose, then 120 mg SC monthly. Cluster: 300 mg SC at onset of cluster period, then monthly during cluster. (1) · Topical cream/lotion BID; shampoo twice weekly; nail lacquer (Penlac) once daily for up to 48 weeks (1)

0.77% topical cream, lotion, suspension; 1% shampoo; 8% nail lacquer (Penlac) (1) · 120 mg/mL prefilled syringe or autoinjector (1) · 225 mg/1.5 mL prefilled syringe or autoinjector (1)

240 mg loading + 120 mg/month for migraine; 300 mg/month for cluster (1) · 675 mg/quarter (1) · BID topical; once daily nail lacquer (1)

Subcutaneous (2) · Topical (1)

None · Hours · 30-60 minutes · 1-2 hours · ~30 min · LDL lowering at 2 weeks, max by 4 weeks · ~1 hour · 15-30 minutes · 15–30 min · 1–2 h · 30–60 min · Antidepressant effect emerges over 1-2 weeks · BP and symptomatic LUTS improvement within 1-2 weeks · BP effect within 1-2 weeks · Clinical improvement within 24-72 hours · Days · Motor improvement over days at therapeutic dose · Over weeks · Postprandial glucose effect within days; HbA1c by 12 weeks · Sleep effect from first dose; antidepressant effect over 1-4 weeks

Other values:

Search

Hours per application (1) · Monthly dosing (1) · Monthly or quarterly dosing (1)

Not meaningfully described (topical local action)'"`UNIQ--ref-00001239-QINU`"' (1) · ~27 days (1) · ~31 days (1)

Not formally established (1) · Not formally established (high SC) (1) · Topical with minimal systemic absorption'"`UNIQ--ref-0000123A-QINU`"' (1)

Generally considered safe (minimal systemic absorption).<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Limited data; avoid (2)

Rx (2) · [[USLegal:Prescription only|Rx-only]] in US (1)